Podcast Music Movie Game Book
  1. 🎧Podcast
  2. 🎧Luke Johnson
  3. 102. The palm is ~0.5% TBSA - Insurance companies denying coverage - Malignancy risk in JAK inhibitors - MACE risk in JAK inhibitors - Oral azoles for head-and-neck dermatitis

102. The palm is ~0.5% TBSA - Insurance companies denying coverage - Malignancy risk in JAK inhibitors - MACE risk in JAK inhibitors - Oral azoles for head-and-neck dermatitis

Release Date:

The palm is ~0.5% TBSA -
Insurance companies denying coverage -
Malignancy risk in JAK inhibitors -
MACE risk in JAK inhibitors -
Oral azoles for head-and-neck dermatitis -
Luke's PDPC course and the Intermountain Derm Society meeting: https://registration.socio.events/e/idspdpc23/promo-codes/ATTENDEE
Connect with us!
- Web: https://dermaspherepodcast.com/
- Twitter: @DermaspherePC
- Instagram: dermaspherepodcast
- Facebook: https://www.facebook.com/DermaspherePodcast/
- Check out Luke and Michelle’s other podcast, SkinCast! https://healthcare.utah.edu/dermatology/skincast/
Luke and Michelle report no significant conflicts of interest… BUT check out our friends at:
- Kikoxp.com(a social platform for doctors to share knowledge)
- https://www.levelex.com/games/top-derm (A free dermatology game to learn more dermatology!)

102. The palm is ~0.5% TBSA - Insurance companies denying coverage - Malignancy risk in JAK inhibitors - MACE risk in JAK inhibitors - Oral azoles for head-and-neck dermatitis
Title
102. The palm is ~0.5% TBSA - Insurance companies denying coverage - Malignancy risk in JAK inhibitors - MACE risk in JAK inhibitors - Oral azoles for head-and-neck dermatitis
Copyright
Release Date

flashback